@misc{indiciae51b673348814,
  title = {Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.},
  author = {Adnan Khattak and Matteo S Carlino and Tarek Meniawy and George Ansstas and Matthew H Taylor and Kevin B Kim and Meredith McKean and Georgina V Long and Ryan J Sullivan and Mark Faries and Thuy T Tran and C Lance Cowey and Andrew Pecora and Theresa Medina and Victoria Atkinson and Clemens Krepler and Thomas Jemielita and Huzhang Mao and Jacky Chow and Laureen S Ojalvo and Janice M Mehnert and KEYNOTE-942 Investigators},
  year = {2026},
  doi = {10.1200/jco-26-00835},
  url = {https://pubmed.ncbi.nlm.nih.gov/42223134/},
  note = {Source identifier: 42223134}
}